Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)e2507821122
JournalProceedings of the National Academy of Sciences of the United States of America
Volume122
Issue number21
DOIs
StatePublished - 27 May 2025

All Science Journal Classification (ASJC) codes

  • General

Cite this